Pipeline

We are advancing our pipeline of Selective Translation Regulator Inhibitors (STRIs) with speed and scale.
Our STRIs are designed to overcome cancer’s complex, aggressive nature. They can augment efficacy of existing therapies and those in development, as well as target the oncoproteins, immune suppression factors and resistance mechanisms cancer frequently uses to evade therapeutic intervention.

Program
(Target)

Discovery

Preclinical

Phase 1

Phase 2a

Phase 2b

Phase 3

Global Rights

Anticipated Milestones

Zotatifin

(eIF4Ai)

Discovery

Preclinical

Phase 1

Phase 2a

Phase 2b

Phase 3

Solid Tumors: ER + BC and KRAS NSCLC
Solid Tumors: ER + BC and KRAS NSCLC
eFFECTOR

H2 2024: RP2D for ZFA triplet

External Collaborations

eIF4Ei

Discovery

Preclinical

Phase 1

Phase 2a

Phase 2b

Phase 3

Solid Tumors
Solid Tumors
Pfizer
$507M deal value with option to co-promote and profit share

Tomivosertib

(MNKi)

Discovery

Preclinical

Phase 1

Phase 2a

Phase 2b

Phase 3

Investigator-initiated trial at Northwestern in r/r AML
Investigator-initiated trial at Northwestern in r/r AML
eFFECTOR

2024: Initial safety and tolerability data from dose-escalation

Zotatifin

(eIF4Ai)

Discovery

Preclinical

Phase 1

Phase 2a

Phase 2b

Phase 3

Investigator-initiated trial at Stanford in ER+ HER2- breast cancer in pre-operative setting
Investigator-initiated trial at Stanford in ER+ HER2- breast cancer in pre-operative setting
eFFECTOR

ZOTATIFIN

A POTENT AND HIGHLY SELECTIVE eIF4A mRNA HELICASE INHIBITOR

Our lead product candidate, zotatifin, is a small molecule inhibitor of eIF4A. eIF4A is a helicase responsible for unwinding complex secondary structures in “onco” mRNAs and enables select tumor cells to overproduce proteins associated with cellular growth, including ER and KRAS. We are conducting multiple Phase 2a expansion cohorts with zotatifin both as a single agent and in combination with targeted agents in ER+ breast cancer and KRAS-mutant NSCLC.

eIF4E

A GLOBAL COLLABORATION WITH PFIZER

Our second program is focused on developing inhibitors of eIF4E. eIF4E is an oncogenic target involved in the translation of key disease driving proteins. These inhibitors are currently being developed by Pfizer under our research collaboration and license agreement. We have retained an option to co-promote and profit share in the United States.

TOMIVOSERTIB

A POTENT AND HIGHLY SELECTIVE MNK INHIBITOR

Tomivosertib is an oral small molecule inhibitor of MNK. Tomivosertib was developed by eFFECTOR and is currently being studied in an investigator led trial by Northwestern University. Tomivosertib has shown an ability to downregulate production of anti-apoptotic proteins including Mcl-1 and Bcl-2, which are critical for survival of leukemic cells. The trial is currently conducting dose-escalation with tomivosertib as monotherapy.